Entera Bio posts 2022 net loss of $13.1M; cash runway into Q3 2024; FDA accepts Type D meeting for EB613

Entera Bio Ltd.

2023-Q1 EPS reported $0.08

Net loss $13.1M ($0.45/share) vs $12.2M ($0.47/share) in 2021; revenues $134K, down from $571K.
Cash and equivalents $12.3M; expects runway into Q3 2024, excluding Phase 3 EB613 funding.
FDA accepted Type D meeting to confirm placebo-controlled Phase 3 design with TH BMD endpoint for EB613.
EB613 (oral teriparatide) positioned as first daily tablet anabolic therapy for osteoporosis; Phase 2 results positive.
New formulation EB612 (PTH(1-34) for hypoparathyroidism) entering Phase 1 PK study, targeting Phase 2 in 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Entera Bio Ltd. reported the fiscal year ended December 31, 2022 results: revenue $134,000, net income $13.1 million, EPS $0.45 per ordinary share (basic and diluted).

Period: the fiscal year ended December 31, 2022
Revenue: $134,000
Net income: $13.1 million
EPS: $0.45 per ordinary share (basic and diluted)
Result: reported results

Exact text from the filing

stated Miranda Toledano, Chief Executive Officer of Entera. Financial Results for the year Ended December 31, 2022 Revenues for the year ended December 31, 2022 and 2021 were $134,000 and $571,000, respectively, mainly attributable to research and development, or R&D services provided to Amgen and other third parties under material transfer agreements. The

View on SEC.gov

Browse all earnings releases →

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-23-001271

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.